Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumor · Chronic Lymphocytic Leukemia

BEONE MEDICINES AUS

BEONE MEDICINES AUS PTY LTD

BEONE MEDICINES AUS drug portfolio — 63 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Cambridge, USA HQ
2010 Founded
3,177 Employees
TGA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
2010
Employees
3,177
Programs
122
Drugs
63
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

BEONE MEDICINES AUS pipeline

Portfolio lens on 63 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

BEONE MEDICINES AUS drug portfolio — 63 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

63 compounds

  1. acalabrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  2. acalabrutinib maleate

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  3. adalimumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  4. adenosine

    US regulatory status: approved. Molecular target: Adenosine receptor.

    Target
    Adenosine receptor
    Mechanism
    Adenosine receptor agonist

  5. anti-

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  6. antibody

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  7. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  8. azacitidine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 3A inhibitor

  9. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  10. blinatumomab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.

    Target
    B-lymphocyte antigen CD19
    Mechanism
    T cell surface glycoprotein CD3 cross-linking agent

  11. calcitriol

    US regulatory status: approved. Molecular target: Vitamin D3 receptor.

    Target
    Vitamin D3 receptor
    Mechanism
    Vitamin D receptor agonist

  12. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  13. capsule

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  14. capsules

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  15. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  16. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  17. combination

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  18. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  19. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  20. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  21. differentiation

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  22. dose-escalation

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  23. escalation

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  24. exagamglogene autotemcel

    Blood and blood forming organs (B06)

    Blood and blood forming organs (B06) compound in BEONE MEDICINES AUS's portfolio. Molecular target: BCL11 transcription factor A.

    Target
    BCL11 transcription factor A
    Mechanism
    B-cell lymphoma/leukemia 11A gene editing negative modulator

  25. glofitamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in BEONE MEDICINES AUS's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  26. hydromorphone

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records. Mechanism: Mu opioid receptor agonist.

    Mechanism
    Mu opioid receptor agonist

  27. idelalisib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform.

    Target
    Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
    Mechanism
    PI3-kinase p110-delta subunit inhibitor

  28. infusion

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  29. inhibitor

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  30. inhibitors

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  31. injection

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  32. insulin human

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  33. maintenance

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  34. monoclonal

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  35. monotherapy

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  36. mosunetuzumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in BEONE MEDICINES AUS's portfolio. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  37. obinutuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  38. ociperlimab

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records. Molecular target: T-cell immunoreceptor with Ig and ITIM domains.

    Target
    T-cell immunoreceptor with Ig and ITIM domains
    Mechanism
    T-cell immunoreceptor with Ig and ITIM domains inhibitor

  39. pamiparib

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase 2 inhibitor

  40. pirtobrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  41. placebo

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  42. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  43. posaconazole

    Antiinfectives for systemic use (J02)

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  44. powder

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  45. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  46. solution

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  48. stro-

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  49. subcutaneous

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  50. suspension

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  51. tablet

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  52. tablets

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  53. tarlatamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in BEONE MEDICINES AUS's portfolio. Molecular target: Delta-like protein 3.

    Target
    Delta-like protein 3
    Mechanism
    Delta-like protein 3 binding agent

  54. tarlatamab-dlle

    US regulatory status: approved. Molecular target: Delta-like protein 3.

    Target
    Delta-like protein 3
    Mechanism
    Delta-like protein 3 binding agent

  55. therapy

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  56. ticarcillin disodium

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  57. tislelizumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in BEONE MEDICINES AUS's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  58. tislelizumab-jsgr

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  59. treatment

    Development asset linked to BEONE MEDICINES AUS in public FDA and regional records.

  60. venetoclax

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.

    Target
    Apoptosis regulator Bcl-2
    Mechanism
    Apoptosis regulator Bcl-2 inhibitor

  61. zanidatamab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in BEONE MEDICINES AUS's portfolio. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  62. zanidatamab-hrii

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  63. zanubrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.